BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q3 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,235 | -18.6% | 32,851 | -2.3% | 0.03% | -15.2% |
| Q2 2023 | $2,745 | +3.4% | 33,641 | -6.1% | 0.03% | +6.5% |
| Q1 2023 | $2,656 | -11.2% | 35,808 | -0.8% | 0.03% | -16.2% |
| Q4 2022 | $2,992 | -99.9% | 36,112 | +306.5% | 0.04% | +8.8% |
| Q3 2022 | $2,522,000 | -19.5% | 8,884 | -1.7% | 0.03% | -10.5% |
| Q2 2022 | $3,133,000 | -54.9% | 9,042 | -43.6% | 0.04% | -47.9% |
| Q1 2022 | $6,942,000 | -35.6% | 16,035 | -23.0% | 0.07% | -29.8% |
| Q4 2021 | $10,777,000 | +11.4% | 20,836 | +4.3% | 0.10% | +7.2% |
| Q3 2021 | $9,677,000 | -11.5% | 19,975 | -17.7% | 0.10% | -12.6% |
| Q2 2021 | $10,933,000 | +21.8% | 24,283 | +3.3% | 0.11% | +13.3% |
| Q1 2021 | $8,973,000 | +20.5% | 23,498 | +0.2% | 0.10% | +16.7% |
| Q4 2020 | $7,448,000 | +26.3% | 23,460 | -1.4% | 0.08% | +15.1% |
| Q3 2020 | $5,895,000 | +45.3% | 23,800 | +54.9% | 0.07% | +40.4% |
| Q2 2020 | $4,056,000 | +225.8% | 15,362 | +133.9% | 0.05% | +160.0% |
| Q1 2020 | $1,245,000 | -9.5% | 6,567 | +4.8% | 0.02% | +11.1% |
| Q4 2019 | $1,375,000 | +3.9% | 6,265 | -7.4% | 0.02% | 0.0% |
| Q3 2019 | $1,323,000 | +45.7% | 6,765 | +55.3% | 0.02% | +20.0% |
| Q2 2019 | $908,000 | +5.6% | 4,356 | +0.5% | 0.02% | 0.0% |
| Q1 2019 | $860,000 | -2.3% | 4,336 | -28.8% | 0.02% | -11.8% |
| Q4 2018 | $880,000 | -47.4% | 6,090 | -25.7% | 0.02% | -39.3% |
| Q3 2018 | $1,673,000 | -3.2% | 8,202 | -29.8% | 0.03% | -9.7% |
| Q2 2018 | $1,728,000 | -5.8% | 11,689 | -3.9% | 0.03% | -18.4% |
| Q1 2018 | $1,835,000 | +50.9% | 12,159 | +29.4% | 0.04% | +31.0% |
| Q4 2017 | $1,216,000 | +61.9% | 9,399 | +51.1% | 0.03% | -23.7% |
| Q3 2017 | $751,000 | +68.4% | 6,219 | +63.7% | 0.04% | +26.7% |
| Q2 2017 | $446,000 | +23.5% | 3,799 | +6.8% | 0.03% | +15.4% |
| Q1 2017 | $361,000 | +3.4% | 3,557 | +4.7% | 0.03% | -21.2% |
| Q4 2016 | $349,000 | -0.6% | 3,397 | +5.8% | 0.03% | -10.8% |
| Q3 2016 | $351,000 | -7.4% | 3,210 | -4.6% | 0.04% | -5.1% |
| Q2 2016 | $379,000 | +49.8% | 3,364 | +25.4% | 0.04% | +50.0% |
| Q1 2016 | $253,000 | +216.2% | 2,683 | +200.4% | 0.03% | +136.4% |
| Q4 2015 | $80,000 | – | 893 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |